Navigation Links
Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
Date:9/10/2009

BATON ROUGE, La., Sept. 10 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide range of cancers including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090421/NE02455LOGO )

"We are pleased to have begun human clinical trials of EP-100 as a novel cancer therapeutic candidate with the potential to offer an improved safety and efficacy profile over existing therapies such as radiation or chemotherapy," said Hector Alila, Ph.D., President of Esperance. "Preclinical studies of EP-100 demonstrated this candidate's efficacy across multiple indications in oncology, including aggressive cancers known to be resistant to the current standards of care and, importantly, studies of EP-100's mechanism-of-action support that it targets and selectively kills cancer cells without harming normal cells."

The Phase 1 study is a multi-center, open-label, dose escalating study designed to evaluate the safety, pharmacodynamic and pharmacokinetic properties of EP-100. This study will enroll adult patients with solid tumors that over-express LHRH receptors as determined by tumor biopsy. Up to a total of 36 patients that are either refractory to the standard of care or for which no standard of care exists may be enrolled in the study. EP-
'/>"/>

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 21, 2015 ... the addition of the "Analysis of the ... their offering. Globally, flow cytometry remains ... cell proliferation, cancer, and stem cells. But the ... primarily because of demand from underdeveloped nations to ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... VetStem ... a live stem cell credentialing course to local area veterinarians. , The tour and ... approved CE units at no charge) at VetStem’s Poway facility. Staff members are welcome ...
(Date:7/28/2015)... YORK , July 28, 2015 Tauriga ... a diversified life sciences company, today announced that its ... shares of common stock of the Company from 1,000,000,000 ... on July 27, 2015 at the Law Offices of ...  At the Special Meeting, there were 480,655,929 shares of ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... Neuftec,Limited, the proprietor of the original nano-particulate ... claim against Oxonica Energy,Limited, a wholly owned subsidiary ... in the High Court of Justice, has commented ... by Dr Matthews,(CEO) on 19 June 2008., ...
... have invented an affordable technique that uses lasers and ... needed for new generations of microchips. , The ... times narrower than a human hair, may enable the ... applications in medicine, optical communications, computing and sensor technologies. ...
... June 18 ,Exelixis, Inc. (Nasdaq: EXEL ) announced ... officer at Exelixis, will present at the,Piper Jaffray Europe ... time on Wednesday, June 25, 2008. Mr. Karbe will ... The presentation will be webcast and may be ...
Cached Biology Technology:Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC's Regulatory Announcement 2Trap and zap: Harnessing the power of light to pattern surfaces on the nanoscale 2Trap and zap: Harnessing the power of light to pattern surfaces on the nanoscale 3
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... Scientists at Albert Einstein College of Medicine of ... (GCE) grants from the Bill & Melinda Gates Foundation ... grant recipients are Arturo Casadevall , M.D., Ph.D., who is ... Ekaterina Dadachova , Ph.D., and Joan Berman , Ph.D., for ...
... of Colorado Boulder has been awarded $9.2 million over five years ... coli to produce biofuels such as gasoline. "This ... for the past decade to the next level," said team leader ... or RASEI. "In this project, we will develop technologies that are ...
... confirms that lions are rapidly and literally losing ground ... growth and subsequent, massive land-use conversion. Representing the most ... savannah habitat to date, the report maintains that the ... in Africa a reduction that has devastated lion ...
Cached Biology News:Einstein researchers receive 2 Grand Challenges Explorations grants to combat HIV and TB 2Einstein researchers receive 2 Grand Challenges Explorations grants to combat HIV and TB 3CU-led team receives $9.2 million DOE grant to engineer E. coli into biofuels 2New study reveals lions are rapidly losing ground in Africa 2New study reveals lions are rapidly losing ground in Africa 3
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Apoptosis Detection Systems and Reagents...
...
...
Biology Products: